CRO PlatformAI-Native CRO OS
Toggle navigationMenu

Capture & bid funnel

agents #32 · #33real + syntheticlive · 30s

Agent #32 scans ClinicalTrials.gov for newly-posted, industry-sponsored trials (real leads, tagged with their NCT id) and adds a synthetic portfolio-derived feed for breadth (tagged ← STUDY). It scores fit, asks the model to qualify each lead (pursue / watch / pass), and drafts human-reviewable outreach for the pursue leads (✉ draft). It maintains the pipeline across scheduled scans — new leads accumulate, duplicates are skipped. Outreach is never sent automatically; advancing the funnel (#33) is human-gated; pricing is human-set; the award is an exec sign-off; promotion to live needs a Part 11 signature.

Sourcing agent health — #32

Stale · last sourced 86d ago

Pipeline

63

Real leads

9

AI-qualified

15

Last 7 days

0

Real leads are public, read-only ClinicalTrials.gov registrations (no PHI, no scraping beyond the API). No sponsor is contacted and no outreach is sent — drafts are staged for a human to review and send (ADR 0013).
Daily scheduleloading…

Sourced

63
  • OPP-FE31fit 85
    Metabolic · Phase 1 · $20–50M
    passsyntheticAI
  • OPP-F406fit 90
    Metabolic · Phase 2 · <$5M
    passsyntheticAI
  • OPP-D401fit 90
    Metabolic · Phase 3 · <$5M
    passsyntheticAI
  • OPP-AECFfit 90
    Rare Disease · Phase 2 · <$5M
    passsyntheticAI
  • OPP-A9ECfit 90
    Metabolic · Phase 2 · <$5M
    passsyntheticAI
  • OPP-F133fit 97
    Rare Disease · Phase 2 · $5–20M
    watchsyntheticAI
  • OPP-0501fit 100
    Metabolic · Phase 4 · $50M+
    pursuesynthetic✉ draftAI
  • NCT07654829fit 100
    Immunology · Phase 4 · $20–50M
    pursueNCT07654829✉ draftAI
  • NCT07654751fit 100
    Immunology · Phase 4 · $20–50M
    pursueNCT07654751✉ draftAI
  • NCT07654361fit 100
    Metabolic · Phase 3 · $50M+
    pursueNCT07654361✉ draftAI
  • NCT07654283fit 100
    Immunology · Phase 2 · $20–50M
    pursueNCT07654283✉ draftAI
  • NCT07654140fit 100
    Cardiology · Phase 2 · $20–50M
    pursueNCT07654140✉ draftAI
  • NCT07654114fit 100
    Immunology · Phase 2 · $20–50M
    pursueNCT07654114✉ draftAI
  • NCT07653685fit 100
    Oncology · Phase 2 · $20–50M
    pursueNCT07653685✉ draftAI
  • NCT07652658fit 100
    Immunology · Phase 2 · $20–50M
    pursueNCT07652658✉ draftAI
  • OPP-DEA4fit 70
    Rare Disease · Phase 3 · $20–50M
    synthetic
  • OPP-3A81fit 70
    Oncology · Phase 1 · <$5M
    synthetic
  • OPP-2DBAfit 70
    Oncology · Phase 4 · <$5M
    synthetic
  • OPP-55DAfit 75
    Rare Disease · Phase 3 · $50M+
    synthetic
  • OPP-FBFCfit 77
    Oncology · Phase 1 · $5–20M
    synthetic
  • OPP-A0A0fit 77
    Immunology · Phase 1 · $5–20M
    synthetic
  • OPP-6388fit 77
    Oncology · Phase 1 · $5–20M
    synthetic
  • OPP-F7EDfit 85
    Immunology · Phase 4 · $20–50M
    synthetic
  • OPP-31BFfit 85
    Immunology · Phase 4 · $20–50M
    synthetic
  • OPP-D64Ffit 90
    Immunology · Phase 3 · <$5M
    synthetic
  • OPP-90A7fit 90
    Oncology · Phase 1 · $50M+
    synthetic
  • OPP-7495fit 90
    Cardiology · Phase 3 · <$5M
    synthetic
  • OPP-C489fit 97
    Immunology · Phase 3 · $5–20M
    synthetic
  • OPP-D4BBfit 100
    Cardiology · Phase 2 · $50M+
    synthetic
  • OPP-7C27fit 100
    Immunology · Phase 2 · $50M+
    synthetic
  • OPP-VAX-014-ADJfit 97
    Immunology · Phase 2 · $5–20M
    pursuesyntheticVAX-014
  • OPP-ONC-002-FUfit 97
    Oncology · Phase 3 · $5–20M
    pursuesyntheticONC-002
  • OPP-ONC-002-ADJfit 97
    Oncology · Phase 2 · $5–20M
    pursuesyntheticONC-002
  • OPP-RARE-007-FUfit 100
    Rare Disease · Phase 4 · $20–50M
    pursuesyntheticRARE-007
  • OPP-RARE-007-ADJfit 97
    Rare Disease · Phase 3 · $5–20M
    pursuesyntheticRARE-007
  • OPP-DERM-003-FUfit 97
    Immunology · Phase 3 · $5–20M
    pursuesyntheticDERM-003
  • OPP-DERM-003-ADJfit 97
    Immunology · Phase 2 · $5–20M
    pursuesyntheticDERM-003
  • OPP-CV-118-FUfit 100
    Cardiology · Phase 4 · $50M+
    pursuesyntheticCV-118
  • OPP-CV-118-ADJfit 100
    Cardiology · Phase 3 · $20–50M
    pursuesyntheticCV-118
  • OPP-VAX-014-FUfit 100
    Immunology · Phase 3 · $20–50M
    pursuesyntheticVAX-014
  • OPP-OBS-PMR-001-FUfit 97
    Metabolic · Phase 4 · $5–20M
    pursuesyntheticOBS-PMR-001
  • OPP-OBS-PMR-001-ADJfit 97
    Metabolic · Phase 4 · $5–20M
    pursuesyntheticOBS-PMR-001
  • OPP-DEA4fit 70
    Rare Disease · Phase 3 · $20–50M
    synthetic
  • OPP-3A81fit 70
    Oncology · Phase 1 · <$5M
    synthetic
  • OPP-2DBAfit 70
    Oncology · Phase 4 · <$5M
    synthetic
  • OPP-55DAfit 75
    Rare Disease · Phase 3 · $50M+
    synthetic
  • OPP-FBFCfit 77
    Oncology · Phase 1 · $5–20M
    synthetic
  • OPP-A0A0fit 77
    Immunology · Phase 1 · $5–20M
    synthetic
  • OPP-6388fit 77
    Oncology · Phase 1 · $5–20M
    synthetic
  • OPP-F7EDfit 85
    Immunology · Phase 4 · $20–50M
    synthetic
  • OPP-31BFfit 85
    Immunology · Phase 4 · $20–50M
    synthetic
  • OPP-D64Ffit 90
    Immunology · Phase 3 · <$5M
    synthetic
  • OPP-90A7fit 90
    Oncology · Phase 1 · $50M+
    synthetic
  • OPP-7495fit 90
    Cardiology · Phase 3 · <$5M
    synthetic
  • OPP-C489fit 97
    Immunology · Phase 3 · $5–20M
    synthetic
  • OPP-D4BBfit 100
    Cardiology · Phase 2 · $50M+
    synthetic
  • OPP-7C27fit 100
    Immunology · Phase 2 · $50M+
    synthetic
  • OPP-3F2Afit 90
    Oncology · Phase 3 · $50M+
    synthetic
  • OPP-0A93fit 75
    Cardiology · Phase 2 · $20–50M
    synthetic
  • OPP-22D0fit 88
    Oncology · Phase 2 · $50M+
    synthetic
  • OPP-91C4fit 82
    Cardiology · Phase 3 · $20–50M
    synthetic
  • OPP-7B11fit 85
    Immunology · Phase 2 · $20–50M
    synthetic
  • OPP-58EEfit 70
    Immunology · Phase 3 · $5–20M
    synthetic

Qualified

0

Bid

0

Proposal

0

Bid defense

0

Awarded

0

Declined

0

Opportunities are staged records — review and sign them in staging.